Szczyrek Michał, Bitkowska Paulina, Jutrzenka Marta, Milanowski Janusz
Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Collegium Medicum, University of Warmia Mazury in Olsztyn, Aleja Warszawska 30, 11-041 Olsztyn, Poland.
J Pers Med. 2022 Jul 27;12(8):1227. doi: 10.3390/jpm12081227.
Lung cancer remains a leading cause of cancer-related deaths worldwide, overtaking colon, breast, and prostate cancer-related deaths. Due to the limited diagnostic possibilities, it is often diagnosed after it has reached an advanced stage. The delayed diagnosis significantly worsens the patient's prognosis. In recent years, we have observed an increased interest in the use of microRNAs (miRNAs) as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC). The abnormal expression levels of the miRNAs could be used to detect NSCLC in its early stages while it is still asymptomatic. This could drastically improve the clinical outcome. Furthermore, some miRNAs could serve as promising predictive and prognostic factors for NSCLC. Some of the currently available studies have shown a correlation between the miRNAs' levels and the sensitivity of tumour cells to different treatment regimens. Analysing and modulating the miRNAs' expression could be a way to predict and improve the treatment's outcome.
肺癌仍然是全球癌症相关死亡的主要原因,超过了结肠癌、乳腺癌和前列腺癌相关的死亡人数。由于诊断可能性有限,肺癌往往在发展到晚期后才被诊断出来。诊断延迟会显著恶化患者的预后。近年来,我们观察到人们对使用微小RNA(miRNA)作为非小细胞肺癌(NSCLC)的诊断、预测和预后标志物的兴趣日益增加。miRNA的异常表达水平可用于在NSCLC仍无症状的早期阶段进行检测。这可能会极大地改善临床结果。此外,一些miRNA可以作为NSCLC有前景的预测和预后因素。目前一些现有研究表明,miRNA水平与肿瘤细胞对不同治疗方案的敏感性之间存在相关性。分析和调节miRNA的表达可能是预测和改善治疗结果的一种方法。